Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs

Peng Xing; Shuo Wang; Yu Cao; Bo Liu; Feifei Zheng; Wei Guo; Junhao Huang; Zimo Zhao; Ziyi Yang; Xingda Lin; Liang Sang; Zhe Liu

doi:10.1016/j.drup.2023.101002

Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs

Drug Resist Updat. 2023 Nov:71:101002. doi: 10.1016/j.drup.2023.101002. Epub 2023 Aug 22.

Authors

Peng Xing¹, Shuo Wang¹, Yu Cao¹, Bo Liu², Feifei Zheng³, Wei Guo⁴, Junhao Huang⁴, Zimo Zhao⁵, Ziyi Yang⁴, Xingda Lin⁴, Liang Sang⁶, Zhe Liu⁷

Affiliations

¹ Department of Surgical Oncology, Breast Surgery, General Surgery,The First Hospital of China Medical University, Shenyang, China.
² Department of Cardiac Surgery,The First Hospital of China Medical University, Shenyang, China.
³ Department of Laboratory Medicine, the Affiliated Hospital of Jiangnan University, Wuxi, China.
⁴ Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, Shenyang, China.
⁵ Department of Ultrasound, The First Hospital of China Medical University, Shenyang, China.
⁶ Department of Ultrasound, The First Hospital of China Medical University, Shenyang, China. Electronic address: 13889167622@163.com.
⁷ Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, Shenyang, China. Electronic address: liuz@cmu.edu.cn.

PMID: 37678078
DOI: 10.1016/j.drup.2023.101002

Abstract

Adenocarcinoma is a common type of malignant tumor, originating from glandular epithelial cells in various organs, such as pancreas, breast, lung, stomach, colon, rectus, and prostate. For patients who lose the opportunity for radical surgery, medication is available to provide potential clinical benefits. However, drug resistance is a big obstacle to obtain desired clinical prognosis. In this review, we provide a summary of treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs, including pancreatic cancer, gastric adenocarcinoma, colorectal adenocarcinoma, lung adenocarcinoma, and prostate cancer. Although the underlying molecular mechanisms involved in drug resistance of adenocarcinoma vary from one organ to the other, there are several targets that are universal for drug resistance in adenocarcinoma, and targeting these molecules could potentially reverse drug resistance in the treatment of adenocarcinomas.

Keywords: Adenocarcinoma; Chemotherapy; Resistance; Treatment; Tumor.

Publication types

Review

MeSH terms

Adenocarcinoma* / drug therapy
Adenocarcinoma* / genetics
Colorectal Neoplasms*
Humans
Male
Pancreatic Neoplasms*
Prostatic Neoplasms*